Phototherapy and mycosis fungoides: what’s new?

Paolo Iacovelli; Alessia Pacifico; Maria Mariano; Diego Orsini; Andrea D'Arino; Flavia Pigliacelli

doi:10.4081/dr.2023.9830

Authors

Paolo Iacovelli
paolo.iacovelli@ifo.it
Clinical Dermatology Unit, San Gallicano Dermatological Institute, Rome, Italy. https://orcid.org/0000-0001-8711-4868
Alessia Pacifico Clinical Dermatology Unit, San Gallicano Dermatological Institute, Rome, Italy.
Maria Mariano Clinical Dermatology Unit, San Gallicano Dermatological Institute, Rome, Italy. https://orcid.org/0000-0002-7964-3388
Diego Orsini Clinical Dermatology Unit, San Gallicano Dermatological Institute, Rome, Italy. https://orcid.org/0000-0002-3190-3988
Andrea D'Arino Oncologic and Preventive Dermatology Unit, San Gallicano Dermatological Institute, Rome, Italy. https://orcid.org/0000-0002-0669-1442
Flavia Pigliacelli Clinical Dermatology Unit, San Gallicano Dermatological Institute, Rome, Italy. https://orcid.org/0000-0003-2118-0795

The most common cutaneous T-cell lymphoma, mycosis fungoides (MF), is clinically characterized by erythematous-violaceous nodules and erythematous-scaly patches. In the early stages of MF, phototherapy is currently the first line of treatment and plays a significant role. This study aims to review and analyze the various phototherapy options for cutaneous lymphoma.

Vaidya T, Badri T. Mycosis fungoides. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2023.

Pileri A, Guglielmo A, Grandi V, et al. The microenvironment's role in mycosis fungoides and sézary syndrome: from progression to therapeutic implications. Cells 2021;10:2780.

Miyashiro D, Souza BCE, Torrealba MP, et al. The role of tumor microenvironment in the pathogenesis of Sézary syndrome. Int J Mol Sci 2022;23:936.

Krejsgaard T, Lindahl LM, Mongan NP, et al. Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. Semin Immunopathol 2017;39:269-82.

Grandi V, Baldo A, Berti E, et al. Italianexpert-basedrecommendations on the use of photo(chemo)therapy in the management of mycosisfungoides: results of an e-Delphiconsensus. Photodermatol Photoimmunol Photomed 2021;37:334-42.

Olsen EA, Hodak E, Anderson T, et al. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol 2016;74:27-58.

Torres AE, Lyons AB, Hamzavi IH, Lim HW. Role of phototherapy in the era of biologics. J Am Acad Dermatol 2021; 84:479-85.

Ahmad K, Rogers S, McNicholas PD, Collins P. Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study. ActaDermVenereol 2007;87:413-7.

Diederen PV, van Weelden H, Sanders CJ, et al. Narrowband UVB and psoralen-UVA in the treatment of early-stage mycosis fungoides: a retrospective study. J Am Acad Dermatol 2003;48:215-9.

Phan K, Ramachandran V, Fassihi H, Sebaratnam DF. Comparison of narrowband UV-B with psoralen-UV-A phototherapy for patients with early-stage mycosis fungoides: a systematic review and meta-analysis. JAMA Dermatol 2019;155:335-41.

Rattanakaemakorn P, Ploydaeng M, Udompanich S, et al. Phototherapy as a treatment of early-stage mycosis fungoides and predictive factors for disease recurrence: a 17-year retrospective study. Indian J Dermatol Venereol Leprol 2021;87:645-50.

Zengarini C, Baruffaldi G, Piraccini BM, et al. Nb-UVB and PUVA therapy in treating early stages of mycosis fungoides: a single-center cross-sectional study. Photodermatol Photoimmunol Photomed 2023;39:435-40.

Adışen E, Tektaş V, Erduran F, et al. Ultraviolet A1 phototherapy in the treatment of early mycosis fungoides. Dermatology 2017;233:192-8.

Zane C, Leali C, Airò P, et al. “High-dose” UVA1 therapy of widespread plaque-type, nodular, and erythrodermic mycosis fungoides. J Am Acad Dermatol 2001;44:629-33.

Trovato E, Pellegrino M, Filippi F, et al. Clinical and histological evaluation in patients with mycosis fungoides treated with UVA1. G Ital Dermatol Venereol 2020;155:306-11.

Rupoli S, Goteri G, Morsia E, et al. Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: long-term efficacy and survival according to conventional and emerging clinical endpoints. Dermatol Ther 2022;35:e15737.

Kim EJ, Mangold AR, DeSimone JA, et al. Efficacy and safety of topical hypericin photodynamic therapy for early-stage cutaneous T-cell lymphoma (mycosis fungoides): the FLASH phase 3 randomized clinical trial. JAMA Dermatol 2022;158:1031-9.

Sosh D, Hyde J, Dulmage B. The efficacy of 308-nm excimer laser in the treatment of mycosis fungoides. Int J Dermatol 2023;62:e92-e93.

Demierre MF, Gan S, Jones J, Miller DR. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 National cutaneous lymphoma foundation survey. Cancer 2006;107:2504-11.

Sampogna F, Frontani M, Baliva G, et al. Quality of life and psychological distress in patients with cutaneous lymphoma. Br J Dermatol 2009;160:815-22.

Graier T, Fink-Puches R, Porkert S, et al. Quality of life, anxiety, and depression in patients with early-stage mycosis fungoides and the effect of oral psoralen plus UV-A (PUVA) photochemotherapy on it. Front Med (Lausanne) 2020;7:330.

Schwarz T. The dark and the sunny sides of UVR-induced immunosuppression: photoimmunology revisited. J Invest Dermatol 2010;130:49-54.

Jones CL, Degasperi A, Grandi V, Amarante TD, Genomics England Research Consortium; Mitchell TJ, Nik-Zainal S, Whittaker SJ. Spectrum of mutational signatures in T-cell lymphoma reveals a key role for UV radiation in cutaneous Tcell lymphoma. Sci Rep 2021;11:3962.

Iacovelli, P., Pacifico, A., Mariano, M., Orsini, D., D’Arino, A., & Pigliacelli, F. (2023). Phototherapy and mycosis fungoides: what’s new?. Dermatology Reports, 16(s2). https://doi.org/10.4081/dr.2023.9830